CS Paper Radar

ScreenShot: A Foundation Model for Few-Shot Combination Drug Screening

Antoine de Mathelin, Christopher Tosh, Wesley Tansey

cs.LG ·submitted 2026-08-12 16:13 UTC · v1
code/data

Abstract

Treating patients with combinations of drugs reduces the risk of resistance to any individual drug. Finding effective combinations is difficult because the large search space makes combinatorial screens prohibitively expensive, time consuming, and often technically infeasible. Predictive models can fill this gap, yet existing methods typically require molecular profiling of each sample and per-cohort training, limiting their applicability when time and tissue are scarce. To address this challenge, we introduce ScreenShot, a hierarchical transformer pretrained on 40 drug screening datasets covering 3,700 drugs and 6,000 biological samples, whose architecture mirrors the nested structure of screening data. Given a few-shot context of observations from a new patient, ScreenShot predicts the response of the sample to combination therapies through in-context learning, operating directly on functional measurements with no fine-tuning and no molecular profiling. On four held-out datasets, ScreenShot outperforms all baselines in both prediction accuracy and identification of selectively effective treatments. ScreenShot's internal representations are directly useful for experimental design: we use them to drive a weighted k-means++ active learning strategy that selects which experiments to run, achieving the same hit detection as uniform screening with a third of the budget. Source code and interactive dashboard: https://github.com/tansey-lab/screenshot.

Closest papers

Nearest neighbours by meaning across the whole index.

Few-Shot Bioactivity Prediction with Meta-Learning under Assay Heterogeneity

cs.LG ·2026-10-05 ·Michal Kmicikiewicz, Tommy Rochussen, Vincent Fortuin, Ewa Szczurek
similarity 0.70
Abstract

Accurate bioactivity prediction is a central challenge in early-stage drug discovery, as individual assays often contain too few measurements to train reliable models independently. Meta-learning offers a principled approach to this few-shot setting, but assay heterogeneity may limit its effectiveness. Here, we test this hypothesis and show that meta-learning performance degrades as meta-training tasks become more heterogeneous. To address this, we introduce MetaHeta, a meta-learning framework that accounts for assay heterogeneity by conditioning predictions on auxiliary data from related assays, with relatedness defined flexibly from available assay information. The architecture of MetaHeta combines linear attention over large auxiliary datasets with exact attention over scarce task-specific context, enabling efficient scaling to the former without compromising exact attention over the latter. We demonstrate the benefits of our approach on assays from ChEMBL and BindingDB, improving few-shot bioactivity prediction and downstream compound prioritization in retrospective Bayesian optimization.

0.17

TabBioMed: A Large-Scale Benchmark for Biomedical Tabular Learning

cs.LG ·2026-11-18 ·Pau Mateo-Bernadó, Saivenkata Nagavyjayanthi Polapragada, David Bonet, Pol Arbiol Rakuljic, Laia Mogas Pladevall +6 more
publishedbenchmarkcode/data similarity 0.69
Abstract · 87 pages, 43 figures, including appendices and the NeurIPS paper checklist

Recent advances in machine learning have accelerated biomedical prediction, but evaluation on structured biomedical data remains fragmented, especially for datasets with high dimensionality, large sample size, missingness, and class imbalance. We introduce TabBioMed, a large-scale benchmark of 94 curated public biomedical tabular datasets spanning electronic health records, drug discovery, genomics, transcriptomics, proteomics, metabolomics, single-cell omics, and systems biology. TabBioMed unifies these datasets through a standardized, dataset-aware preprocessing and evaluation framework, enabling reproducible comparison across classification, regression, and multi-target tasks. We benchmark 23 models across classical baselines, gradient-boosted trees, neural tabular architectures, and tabular foundation models. Foundation models deliver the strongest family-level predictive performance. However, their gains are regime-dependent: tree-based models and tuned multilayer perceptrons remain highly competitive, often dominating under inference-time or training-cost constraints. Overall, TabBioMed shows that biomedical tabular learning is strongly context-dependent, with optimal model choice depending on data regime, task type, and computational budget. We release TabBioMed with curated datasets and splits, preprocessing code, baselines, and results, providing a reproducible benchmark for practical model selection and future methods development in biomedical machine learning, available at https://github.com/AI-sandbox/TabBioMed.

0.44

Beyond Fixed Acquisition Functions: Temporal Difference Active Learning for Perturbation Discovery

cs.LG ·2026-10-15 ·Xudong Zhang, Jianzhe Li, Yitong Tang, Peijie Zhou
similarity 0.69
Abstract · 41 pages, 8 figures (including appendices)

Genetic and drug perturbation screens are important tools for elucidating disease mechanisms and validating therapeutic targets, but experimental costs limit the number of candidates that can be tested. Existing perturbation screening methods typically update the surrogate model with feedback while keeping the acquisition function fixed, limiting their ability to adapt selection to different response landscapes. Experimental feedback reveals current hits and informs subsequent selection by updating candidate predictions, providing a training signal for learning how to select experiments. We formulate budgeted perturbation discovery as a sequential decision problem and propose Temporal Difference Active Learning (TDAL), which learns an acquisition function online through temporal difference learning from a single screening trajectory, accounting for current hits and future discoveries. TDAL uses the Hellinger distance between hit probabilities for unmeasured candidates before and after an experiment to weight successor value, and reuses measured outcomes through leave-batch-out (LBO) to construct virtual transitions and alleviate training data scarcity. Across eight public screens spanning single, double, and triple perturbations under varied experimental configurations, TDAL achieves an average rank of 1.63 among eleven methods and ranks first on four tasks, demonstrating its adaptability across response landscapes.

0.27

PETA:Parameter-Efficient Test-Time Adaptation for Virtual Screening

cs.LG ·2026-08-20 ·Jia-Qi Lin, Yinghua Yao, Chang-Dong Wang, Yew-Soon Ong, Yuangang Pan
similarity 0.68
Abstract

Accurately ranking active ligands for a target protein pocket from massive chemical libraries remains a central challenge in virtual screening. DrugCLIP and its recent extensions substantially accelerate this process by encoding protein pockets and molecules into a shared embedding space. Despite this progress, further performance improvements typically require retraining the entire model, incurring substantial computational overhead and making target-specific customization inefficient. In this work, we formulate the specialization of pretrained virtual screening models to individual pockets as a test-time adaptation problem and propose PETA, a parameter-efficient framework that directly adapts pretrained model at test time. Given a target pocket, PETA constructs pocket-specific negatives through molecular diffusion and chemical validity filtering, and further moves them toward the reference ligand retrieved from structural databases via embedding-space mixup to create more challenging ranking tasks. A ranking objective then places greater emphasis on suppressing high-scoring invalid candidates that could contaminate the top-ranked screening results, providing structured supervision for lightweight adaptation. Experiments across diverse benchmarks demonstrate that this lightweight, pocket-specific adaptation outperforms both pretrained and fully retrained baselines while updating only the LayerNorm parameters, which account for approximately $0.03\%$ of the full model.

0.16

Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling

cs.LG q-bio.QM ·2026-08-11 ·Vincent Lavelle, Yitan Zhu, Kaitlyn Marlor, Thomas Brettin, Rick Stevens
benchmarkdataset similarity 0.68
Abstract

Drug response prediction (DRP) models are an active area of research in pharmacogenomics, with growing potential to accelerate the identification of effective anticancer drugs. However, their predictive performance is often constrained by limited dataset scale and insufficient coverages of cancer and chemical spaces. In addition, inconsistent benchmarking practices hinder reliable comparison across models. Standardized frameworks, such as the Innovative Methodologies and New Data for Predictive Oncology Model Evaluation (IMPROVE) project, provide unified data schemas and evaluation protocols for consistent benchmarking, but improving model generalizability requires larger and more diverse training data. In this work, we substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data, primarily from PharmacoDB, together with additional smaller data sources. The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity, adding more than 50,000 compounds. To evaluate the impact of the new dataset compared to the original IMPROVE benchmark dataset, we trained DRP models using the two datasets and assess their prediction performance using a common test set and several evaluation strategies, including drug-blind, cancer-blind, and disjoint data splits. While cancer-blind performance remained comparable to the original benchmark, models trained on the expanded dataset showed consistent improvements in drug-blind and disjoint settings, indicating enhanced generalization to previously unseen compounds. These results position the expanded dataset as a community resource that provides a richer foundation for developing DRP models intended to aid in the discovery of novel anticancer drugs.

0.04

Molecular Prior Networks

cs.LG cs.AIcs.CE ·2026-11-03 ·Pawel Gomoluch, Anthony Bradley
publishedbenchmark similarity 0.67
Abstract · Accepted to the NeurIPS 2026 Workshop on AI for Drug Discovery: Bridging the Translation Gap

Predicting affinity between small molecules and their protein targets remains one of the central problems in drug discovery. Due to the substantial cost of wet-lab experiments, machine learning models of drug-target affinity are usually trained on relatively small datasets, ranging from tens to hundreds of molecules. Given the inherent difficulty of generalization between different targets and chemical series, existing datasets of protein-ligand affinities are typically not used for new projects. At the same time, tabular foundation models, including Prior-data Fitted Networks, have recently shown how transformers can be used to solve machine learning problems in a single forward pass of the network, after being trained over a large corpus of, typically, synthetic datasets. Inspired by that line of work, we propose a novel affinity modelling approach, in which the labels of the query molecules are predicted from the labelled support molecules in a single forward pass of a transformer model. The model is trained on thousands of existing affinity datasets, enabling it to capture the general patterns of molecular activity across different targets, chemical series and dataset sizes. For the smallest support sets, our model matches the state of the art on the regression variant of the FS-Mol benchmark, while being faster than existing methods, thanks to the lack of task-specific training. A comparison against a reduced variant of our architecture, which amounts to kernel regression in a meta-learned feature space, shows that the predictive performance of the transformer model is only partially explained by simple molecular similarity.

0.25

Disease-level drug approval forecasting from trial-agnostic public data

cs.LG q-bio.QM ·2026-09-29 ·Samir Townsley, Pagkratios Tagkopoulos, Ilias Tagkopoulos
similarity 0.66
Abstract

Drug development is an expensive and lengthy process requiring developers to select drugs for human trials and diseases to target. Computational tools that can estimate before testing which drug-disease candidates are most likely to reach FDA approval could reduce development time and costs through early program advancement and disease prioritization. Yet existing approaches predict outcomes at a single level or stage or do not distinguish between disease outcomes for the same drug. We ask (1) whether FDA approval can be forecast for a drug-disease pair using only pre-clinical trial information, and (2) whether these forecasts can help prioritize diseases for the same drug. We built a cohort of 14,134 drug-disease pairs by reconstructing programs from ClinicalTrials.gov, extracting disease-level approvals from FDA label documentation, and enriching each pair with molecular, disease, ADMET, target, and pathway features. We divided the cohort into pre- and post-2019 programs and trained a classifier on pre-2019 data to predict FDA approval. On the post-2019 cohort (2,637 programs), the model would have prioritized a program that ultimately gained approval over one that did not approximately three out of four times. For drugs tested across multiple diseases, selecting the model's highest-ranked disease would have identified an ultimately approved disease 61.3% of the time, compared with 40.7% under random selection. These results show that public pre-trial information contains signal for forecasting FDA approval at the drug-disease level and can help prioritize diseases for the same drug. We provide a public web tool for SMILES- and ICD-10-based drug-disease approval forecasting.

0.14

Feature Selection for Tabular Foundation Models: Exploring Feature Utility in Low-Data Molecular Prediction

cs.LG ·2026-09-25 ·Yiqi Yao, Miquel Duran-Frigola
code/data similarity 0.66
Abstract · 34 pages, 13 figures, 21 tables, 11 appendices. v3: revised and expanded with held-out FS-Mol test evaluations. Code: https://github.com/ers…

Choosing features is difficult with few labeled molecules, even for a tabular foundation model that learns in context. We study this problem with TabPFN for low-data molecular property prediction, separating input width, feature meaning, and predictive usefulness while keeping contexts, query molecules, and predictor settings matched. On ADME/Tox assays from Therapeutics Data Commons, endpoint-matched assay predictions improve a compact RDKit descriptor baseline, and a provenance audit shows that most audited query molecules already occur in the predictors' training sources. Across 77 FS-Mol development tasks and 157 held-out test assays drawn from ChEMBL, broad RDKit descriptor and fingerprint families provide a strong default, rank-averaging TabPFN with support-fitted fingerprint forests improves upon both models, and learned weighting of family predictions adds further gains at a larger prediction budget. A utility-trained selector builds a traceable 16-column input from 238 sourceassay predictors, improving upon the baseline while trailing wider representations and equalwidth structural SVD coordinates. Named outputs identify what each feature predicts and where it comes from. Their usefulness for a new assay is assessed alongside the other input features, and paired removal and replacement tests measure what each selected output contributes. Together, these studies offer a protocol for evaluating feature selection, representation choice, and data provenance with a fixed tabular foundation model for few-shot molecular property prediction.

0.36